ResApp Health (ASX:RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, has updated on its US clinical study program.
ResApp said it is currently in advanced negotiations with two major US hospitals as sites for ResApp’s paediatric clinical study.
"Both hospitals rank among the top 10 nationally in the US and see in excess of 60,000 patients annually at their emergency departments," said the company.
"These sites will allow fast enrolment of large numbers of patients and provide the highest quality clinical results for submission to the US Food and Drug Administration (FDA). Discussions with two additional clinical study sites in the US are also underway," it added.
The company said it expects these negotiations to conclude in July, with clinical studies to begin shortly thereafter.